Dendreon Announces Webcast Presentations at Upcoming Conferences

SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences:

  • Credit Suisse Healthcare Conference in Phoenix, Arizona on November 9, 2011 at 8:00 a.m. MT
  • Lazard Healthcare Conference in New York City, NY on November 15, 2011 at 9:00 a.m. ET

The presentations will be webcast live and available for replay from Dendreon's website, If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit


Dendreon Corporation
Katherine Stueland, V.P. Corporate Communications & Investor Relations, 206-829-1522

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical



Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.